Wockhardt Files EMA Application for Novel Antibiotic WCK 5222
ECONOMY & POLICY

Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Related Stories

Gold Stories

Next Story
Infrastructure Urban

KONE Opens India's First Digital Experience Centre in Pune

KONE, a global elevator and escalator manufacturer, has inaugurated its first Digital Experience Centre (DEC) in India, located in Pune. The facility aims to showcase how artificial intelligence (AI), connectivity and data-driven technologies can enhance customer experiences and improve building operations.The centre was inaugurated by Jussi Herlin, Executive Vice Chair, KONE Corporation; Philippe Delorme, President and CEO, KONE; and Nandan Nilekani, Co-founder and Chairman of the Board, Infosys.Designed as an interactive customer environment, the facility demonstrates digital solutions cover..

Next Story
Infrastructure Urban

CII GreenCo Launches Circularity Guidelines for Indian Industry

The Confederation of Indian Industry (CII) GreenCo Council has launched the CII GreenCo Circularity Guidelines – Pilot Version at the 17th CII GreenCo Waste & Resource Management Summit 2026 in Chennai. The initiative aims to strengthen resource efficiency, waste reduction and circular economy practices across Indian manufacturing and process industries.The guidelines introduce a structured framework with circularity indices covering raw materials, consumables, packaging and other resource inputs. These indicators will help industries assess existing practices, identify opportunities to ..

Next Story
Infrastructure Energy

Global Electronics Association Launches IPC-1783-CO2E Standard

The Global Electronics Association has introduced IPC-1783-CO2E, a new international standard aimed at improving consistency, transparency and comparability in product carbon footprint reporting across the electronics manufacturing industry.The standard, titled International Standard for Data Collection and Reporting of CO2 Equivalent (CO2e) Emissions for the Electronics Manufacturing Supply Chain, provides industry-specific guidance for collecting, estimating and reporting carbon emissions data.With increasing regulatory requirements and customer expectations, electronics manufacturers face c..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code